Tyrosine kinase inhibitors in glioblastoma (Homo sapiens)
From WikiPathways
Description
"Therapeutic tyrosine kinase inhibitors and anti-EGFR monoclonal antibodies in glioblastoma anti-EGFR mAbs bind the EGFR extracellular domain, preventing EGFR dimerization and subsequent activation. Tyrosine kinase inhibitors (TKIs) target the intracellular TK domain, blocking subsequent receptor tyrosine kinase pathways (RTKs)" From Figure F3 in https://pmc.ncbi.nlm.nih.gov/articles/PMC10967338.
Derived from https://pfocr.wikipathways.org/figures/PMC10967338__antibodies-13-00025-g003.html
Quality Tags
Ontology Terms
Bibliography
- Manzanares-Guzmán A, Lugo-Fabres PH, Camacho-Villegas TA; ''vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target.''; Antibodies, 2024 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
View all... |
Annotated Interactions
No annotated interactions